Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug MAR001 targets high triglycerides in early trial

NCT ID NCT05896254

Disease control Sponsor: Marea Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new medicine, MAR001, in 55 adults with high triglycerides (a type of fat in the blood) and metabolic problems. The main goal was to see if the drug is safe and tolerable. Researchers also checked if it could lower triglyceride levels. The study was completed and compared MAR001 to a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

55 people

The number who actually took part.

Started

Jul 2023

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willingness to provide informed consent and comply with the intervention * Women of childbearing potential and men agreeing to use an appropriate method of contraception for the duration of the study * Evidence of metabolic dysfunction at screening (triglyceride levels \> 2.8 mmol/L) Exclusion Criteria: * Any condition which in the opinion of the investigator prevents the participant from complying with study procedures or prevents the participant from completing the study or interferes with the interpretation of study results * Pregnant or breastfeeding mothers * Terminal illness with expected survival of less than 1 year Note: additional inclusion/exclusion criteria may apply, per protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertriglyceridemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertriglyceridemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertriglyceridemia

Contacts and locations

Locations

  • Brisbane Site

    Brisbane, 4006, Australia

  • Melbourne Site

    Melbourne, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.